Welcome to the Podiatry Arena forums, for communication between foot health professionals about podiatry and related topics.
You are currently viewing our podiatry forum as a guest which gives you limited access to view all podiatry discussions and access our other features. By joining our free global community of Podiatrists and other interested foot health care professionals you will have access to post podiatry topics (answer and ask questions), communicate privately with other members (PM), upload content, view attachments, receive a weekly email update of new discussions, earn CPD points and access many other special features. Registered users do not get displayed the advertisments in posted messages. Registration is fast, simple and absolutely free so please, join our global Podiatry community today!
If you have any problems with the registration process or your account login, please contact contact us.
One of the big problems in wound dressing research is that some new wound dressing is often compared to a "standard" wound dressing. Invariably the "standard" wound dressing is often just sterile gauze (who uses that anyway ), so of course the new dressing is superior. The beauty of this research below is that it compared two good dressings...
Randomized Clinical Trial Comparing OASIS Wound Matrix to Regranex Gel for Diabetic Ulcers.
Niezgoda JA, Van Gils CC, Frykberg RG, Hodde JP; OASIS Diabetic Ulcer Study Group.
Adv Skin Wound Care. 2005 Jun;18(5):258-266.
Quote:
OBJECTIVE: To compare healing rates at 12 weeks for full-thickness diabetic foot ulcers treated with OASIS Wound Matrix, an acellular wound care product, versus Regranex Gel.
DESIGN: Randomized, prospective, controlled multicenter trial at 9 outpatient wound care clinics. SUBJECTS: A total of 73 patients with at least 1 diabetic foot ulcer were entered into the trial and completed the protocol. INTERVENTION: Patients were randomized to receive either OASIS Wound Matrix (n = 37) or Regranex Gel (n = 36) and a secondary dressing. Wounds were cleansed and debrided, if needed, at a weekly clinic visit. Dressings were changed as needed. The maximum treatment period for each patient was 12 weeks. PRIMARY OUTCOME MEASURE: Incidence of healing in each group at 12 weeks.
RESULTS: After 12 weeks of treatment, 18 (49%) OASIS-treated patients had complete wound closure compared with 10 (28%) Regranex-treated patients.
CONCLUSION: Although the sample size was not large enough to demonstrate that the incidence of healing in the OASIS group was statistically superior (P = .055), the study results showed that treatment with OASIS is as effective as Regranex in healing full-thickness diabetic foot ulcers by 12 weeks.
Oasis and Regranex are 2 seperate modalities to heal a wound. Oasis is a collagen matrix, while Regranex is a recombinent DNA growth factor to encourage angiogenesis. The 2 together have a symbiotic effect of wounds... :)
these two are distinctive modalities with symbiotic potential.however,this isn't the way they are detailed.i too agree that for the cost oasis is a superior product.
I get very good results with regranex,indeed it became a first line treatment(for me anyway) for diabetic ulcers.Oasis is great for the more recalcitrant wounds.
The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data.
Persson U, Willis M, Odegaard K, Apelqvist J. Value Health. Nov-Dec;3 Suppl 1:39-46.
Quote:
OBJECTIVES: The objective of this study was to develop a model capable of assessing the cost-effectiveness in Sweden of treating diabetic neuropathic lower extremity ulcers with becaplermin gel (Regranex) plus good wound care (GWC) relative to treating them with GWC alone.
METHODS: A Markov simulation model was developed that includes six health states: Uninfected Ulcer, Infected Ulcer, Gangrene, Healed Ulcer, Healed Ulcer-History of Amputation, and Deceased. To predict clinical outcomes, information was taken from a specially designed prospective 9-month follow-up study of 183 neuropathic patients in the US treated with GWC. Cost of treatment data were taken primarily from a study of a cohort of 314 patients in Sweden. The efficacy of becaplermin was assumed equal to that achieved in a pooled analysis of four randomized clinical trials. A model application provides expected clinical outcomes for a cohort of patients. Annual treatment costs per patient were estimated using treatment practice and unit prices from Sweden.
RESULTS: Due to a higher rate of healing and a shorter average healing time, treatment with becaplermin gel was predicted to increase the average number of months spent in the healed state over the first year following development of an ulcer by 24% relative to GWC alone. In addition, the corresponding number of amputations was 9% lower for the becaplermin-treated cohort. The average expected cost of $12,078 US for an individual treated with GWC alone declines to $11,708 US for one treated with becaplermin, in spite of $1262 becaplermin costs. Expenses related to topical treatment and inpatient care account for 83% of the resources conserved.
CONCLUSIONS: Our results suggest that in Sweden treatment with becaplermin in conjunction with GWC consumes fewer resources and generates better outcomes than treatment with GWC alone for diabetic neuropathic ulcers. In light of the high and increasing incidence of such ulcers, the potential savings in costs and suffering may be important. Results are difficult to extrapolate internationally because they are strongly related to country-specific treatment practices and price levels.
OASIS vs Regranex Gel
), so of course the new dressing is superior. The beauty of this research below is that it compared two good dressings...
Linear Mode
